
- AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high.
- Shares have strong technical momentum and a 100% “Buy” opinion from Barchart.
- Analyst sentiment remains bullish, but Wall Street thinks earnings and revenue will decline next year.
- More than 30% of the float is sold short, creating another reason for caution with ANAB.